Few investors get excited about O-rings, hydraulic seals, wiring, aerospace fasteners or diagnostic consumables. Diploma built its reputation on exactly those products. It rarely makes them; it sources, stocks, adapts and delivers them quickly to engineers who cannot afford downtime. Because the parts are cheap next to the cost of a stalled production line or grounded aircraft, customers prize speed and reliability over price, which gives Diploma pricing power that ordinary distributors lack.
The other half of the story is Capital allocation: Diploma pairs steady organic growth with a constant flow of small, bolt-on acquisitions, most of them bought at single-digit multiples of operating profit. According to the company, adjusted Earnings Per Share compounded at roughly 18% a year over the seven years to FY25, and the full-year Dividend has now risen for 25 consecutive years. FY26, which ends on 30 September, looks like its best yet, with guidance raised three times since March.
How the Business makes money
Diploma (LSE:DPLM) describes itself as a decentralised, value-add distributor. It runs 17 businesses across three sectors, employs around 3,400 people and keeps a head office of only about 40. Local managers run their businesses; the centre allocates capital.
In FY25, Controls produced 55% of revenue. It supplies wiring, interconnect components and fasteners to aerospace, defence, industrial and energy customers. Seals provided 29%, largely heavy-equipment aftermarkets, and Life Sciences 16%, mainly diagnostic and clinical consumables. By region, North America accounted for 53% of FY25 revenue, Europe 19%, the UK 18% and Australia and other markets 10%.
The money comes from added value, not volume: kitting, cutting to length, technical advice, deep inventory and next-day delivery support unusually high margins for a distributor.
Recent performance
In the year to 30 September 2025, Revenue rose 12% to £1,524.5m, with organic growth of 11%. Adjusted operating profit increased 20% to £342.7m, taking the Margin up 160 basis points to 22.5%. Adjusted EPS grew 21% to 176.0p. Free Cash Flow rose 25% to £247.2m, a conversion rate of 105%, and return on adjusted trading capital employed (ROATCE) reached 20.9%. The full-year dividend went up 5% to 62.3p.
Growth then accelerated. In the six months to 31 March 2026, revenue climbed 17% to £851.1m, including 15% organic growth. Adjusted operating profit jumped 33% to £208.9m, lifting the margin to 24.5% from 21.5%. Adjusted EPS rose 36% to 109.2p, while statutory EPS rose only 4% to 74.7p, mainly because of acquisition-related charges. Leverage fell to 0.8 times, ROATCE improved to 22.7% and the Interim Dividend rose 5% to 19.1p.
Controls did most of the work, delivering 26% organic growth on the back of strong aerospace, defence, data-centre and energy demand. Seals managed 2% organic growth: North America grew 7%, while the international business slipped 1% as the UK stayed soft. Life Sciences grew 4% despite tough healthcare markets.
The Q3 trading update on 16 July 2026 reported 15% organic growth for the nine months to 30 June. It raised FY26 guidance to 14% organic growth, an Operating Margin of about 26.5% and operating profit growth of around 42% at constant currency. That compares with original guidance in November 2025 of 6% organic growth and a 22.5% margin.
Strategy and catalysts
In the 12 months to the interim results, Diploma completed 15 deals for about £310m at an average multiple of 8 times, and expected them to add around £40m of annualised operating profit. The largest recent deal, CDM, a US interconnect business focused mainly on defence and priced at around $80m, completed on 25 June 2026. Management sees it as a platform for a larger US interconnect presence. Deals are meant to add exposure to attractive end markets, deepen regional coverage or extend capabilities.
The next catalyst is the full-year results on 17 November 2026. Investors will want FY27 guidance and a view on how durable the Controls boom is. The finance team has changed recently: CFO Chris Davies resigned in August 2025 and Wilson Ng stepped into the role. David Lowden chairs the board, and Johnny Thomson remains chief executive.
Valuation talking points
Diploma is generally valued as a quality compounder rather than an industrial distributor. On 18 March 2026, the company said its upgraded guidance pointed to operating profit about 13% above the consensus of £377m. Later upgrades added a further 6% at the interims and 7% in July. Rising forecasts support a premium rating but raise the bar for FY27.
Central to the case is the gap between the 8 to 9 times profit Diploma pays for acquisitions and the multiple the market puts on its own earnings: while it can reinvest at those prices and earn returns above 20%, each deal adds value. The dividend's 5% increases lag earnings growth, showing management prefers reinvestment to a higher payout.
The bull case
- Organic growth of 15% in the nine months to 30 June 2026, with margin guidance raised from 22.5% to about 26.5% within one year.
- Exposure to defence, aerospace, data-centre and energy growth themes.
- A repeatable Acquisition model with bolt-ons bought at around 8 to 9 times profit, supported by low leverage of 0.8 times.
- ROATCE above 22% and strong cash generation.
- A 25-year run of dividend increases and a long record of compounding EPS.
The bear case
- FY26 results are unusually strong, and management had initially described the organic growth as weighted towards the first half, so comparisons for FY27 will be demanding.
- Growth depends heavily on Controls. Seals and Life Sciences grew by only low single digits in the first half, with softness in the UK and in healthcare markets.
- Statutory EPS grew far more slowly than adjusted EPS, showing that acquisition Amortisation and related costs are significant.
- With over half of revenue from North America, results are exposed to sterling-dollar swings and US trade policy.
- Larger deals such as CDM carry more integration risk than small bolt-ons.
The bottom line
Diploma shows how dull components, niche service and disciplined capital allocation can compound. FY26 is heading for record margins and operating profit growth of around 42%, powered mainly by the Controls businesses serving aerospace, defence and data-centre customers.
The question is less whether the model works than how much of the recent surge lasts. The 17 November results should show whether Seals and Life Sciences are recovering, how CDM is bedding in and what management expects as growth normalises.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...